Evidence map›Paper›PMID 42104930›Full record

ArticleThe oncologist2026

Selective internal radiotherapy and chemosaturation show equivalent survival in metastatic uveal melanoma: a retrospective multicenter study.

Elias A T Koch, Louisa A Schielein, Markus Reitmajer, Ann-Christine Glaser, Konstantin Drexler, Cindy Franklin, Andrea Forschner, Carola Berking, Jessica C Hassel, Markus V Heppt and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elias A T KochDepartment of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, 91054, Germany.ORCID 0000-0003-2005-7533
Louisa A SchieleinHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, 69120, Germany.
Markus ReitmajerDepartment of Dermatology, Center for Dermatooncology, University Hospital Tübingen, Tübingen, 72076, Germany.
Ann-Christine GlaserDepartment of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 50937, Germany.
Konstantin DrexlerDepartment of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Cindy FranklinDepartment of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, 50937, Germany.
Andrea ForschnerDepartment of Dermatology, Center for Dermatooncology, University Hospital Tübingen, Tübingen, 72076, Germany.
Carola BerkingDepartment of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, 91054, Germany.
Jessica C HasselHeidelberg University, Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and University Hospital Heidelberg, Heidelberg, 69120, Germany.
Markus V HepptDepartment of Dermatology, Uniklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, 91054, Germany.
German Dermatologic Cooperative Oncology Group (DeCOG, Committee Ocular Melanoma)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic uveal melanoma (UM) primarily affects the liver, and due to low response rates to systemic therapies, liver-directed therapies (LDT) are commonly used for hepatic tumor control. Direct head-to-head trials comparing these LDTs are still lacking.

methodsA retrospective multicenter explorative analysis was conducted to evaluate the clinical outcomes of transarterial chemoembolization (TACE), selective internal radiotherapy (SIRT), and percutaneous hepatic perfusion (PHP, chemosaturation).

resultsThe present analysis was conducted on a cohort of 121 patients who had been treated for metastatic UM with LDT at five different skin cancer centers. A total of n = 15 patients received TACE (12.4%), n = 51 SIRT (42.1%), and n = 55 PHP (45.5%). The estimated median overall survival (OS) for SIRT was 25.1 months (95% confidence interval [CI], 15.3-34.8), for TACE, 11.4 months (95% CI, 7.8-14.9), and for PHP, 24.9 months (95% CI, 13.7-36.0). In the multivariate analysis that included LDH and additional systemic therapies, there was no significant difference in OS between SIRT and PHP (HR 1.14, 95% CI 0.67-1.93, P = .63), whereas TACE was found to be associated with a substantially reduced in OS compared to PHP (HR 3.25, 95% CI 1.31-8.04, P = .01). Adverse events occurred in 41.6% of patients undergoing SIRT, 64.3% of patients receiving TACE, and 84.6% of patients receiving PHP.

conclusionThe findings of this study indicate that SIRT and PHP demonstrate equivalent survival rates in a real-world setting.

Indexed as

Chemoembolization, TherapeuticLiver NeoplasmsMelanomaUveal NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedRetrospective StudiesUveal Melanomaliver-directed therapiesmetastatic uveal melanomamultidisciplinary tumor boardpercutaneous hepatic perfusionreal-world evidenceselective internal radiotherapyuveal melanoma

Identifiers

PMID42104930
PMCPMC13198371

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.